Brought to you by 
UCL spin-off Magnus Life Science completes £15.5mm seed round
29 Oct 2014
Executive Summary
An undisclosed private equity firm, new to the health care industry, provided Magnus Life Science (pharmaceuticals and devices) with £15.5mm ($24.8mm) in seed financing. The company concurrently received £11.5mm in grant funding from the European Commission Framework 7.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
UCL spin-off Magnus Life Science completes £15.5mm seed round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice